Literature DB >> 866810

Role of prostaglandins in alveolar hypoxic vasoconstriction.

C A Hales, E Rouse, I A Buchwald, H Kazemi.   

Abstract

The role of prostaglandins as mediators of alveolar hypoxic vasoconstriction was investigated in dogs with the use of the prostaglandin synthesis inhibitors, aspirin and indomethacin. Alveolar hypoxia was induced by inserting double-lumened endotracheal tube into the carina and ventilating one lung with nigrogen while maintaining normal systemic oxygenation with 100% O(2) ventilation to the other lung. Relative perfusion to each lung was determined with 133Xenon and external counters. Infusions up to 25 mg/kg of indomethacin and up to 250 mg/kg of aspirin did not block the shift in perfusion from the alveolar hypoxic lung. In fact, the shift in perfusion from the alveolar hypoxic lung was slightly augmented by aspirin (P = 0.03). Thus, no positive role was demonstrated in the dog for prostaglandins in producing the vasoconstriction of alveolar hypoxia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 866810     DOI: 10.1016/0034-5687(77)90088-3

Source DB:  PubMed          Journal:  Respir Physiol        ISSN: 0034-5687


  4 in total

1.  Halothane inhibits hypoxic pulmonary vasoconstriction in the presence of cyclooxygenase blockade.

Authors:  D Johnson; I Mayers; T Hurst
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

2.  Role of cytochrome P-450 in alveolar hypoxic pulmonary vasoconstriction in dogs.

Authors:  M A Miller; C A Hales
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

3.  Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction.

Authors:  L J Rubin; J D Lazar
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

Review 4.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.